What does symproic and other — 2026 mean?

Represents the projected or actual financial performance metric for the Symproic segment specifically for the fiscal year 2026. This serves as a forward-looking data point for evaluating the segment's contribution to long-term revenue or asset valuation.

Collegium Pharmaceutical, Inc. COLL Symproic and other — 2026

Other product segments

Jornay PM

$62.87M0.0%

Belbuca

$56.54M0.0%

Symproic

$5.46M0.0%

Similar metrics at other companies

DCOStructural Systems — 2026

$7.44M-0.3%

DCOElectronic Systems — 2026

$9.29M0.0%

DCOStructural Systems — 2027

$7.44M0.0%

DCOElectronic Systems — 2027

$9.29M0.0%

DCOElectronic Systems — 2029

$5.28M-43.2%

NDAQOther — 2027

$7M0.0%

Other financials

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

See full

Market cap$1.15B+20.4%

Enterprise value$869.67M+2.5%

P/E15.4×-6.4×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.

The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — 2026.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s symproic and other — 2026?: Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — 2026 of $7.29M in Q4 2025.
What does symproic and other — 2026 mean?: Represents the projected or actual financial performance metric for the Symproic segment specifically for the fiscal year 2026. This serves as a forward-looking data point for evaluating the segment's contribution to long-term revenue or asset valuation.